Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease

被引:0
|
作者
Keiji Fujiwara
Koji Furuuchi
Akio Aono
Fumiko Uesugi
Tatsuya Shirai
Keitaro Nakamoto
Takafumi Shimada
Fumi Mochizuki
Yoshiaki Tanaka
Hiroaki Iijima
Takashi Yoshiyama
Yuji Shiraishi
Atsuyuki Kurashima
Ken Ohta
Satoshi Mitarai
Kozo Morimoto
机构
[1] Fukujuji Hospital,Respiratory Disease Center
[2] Japan Anti-Tuberculosis Association,Department of Mycobacterium Reference and Research
[3] The Research Institute of Tuberculosis,Department of Respiratory Medicine
[4] Japan Anti-Tuberculosis Association,Department of Respiratory Medicine
[5] Kyorin University School of Medicine,Division of Clinical Research
[6] Tsukuba Medical Center,undefined
[7] Fukujuji Hospital,undefined
[8] Japan Anti-Tuberculosis Association,undefined
关键词
Treatment outcomes; Lung disease; Cavity;
D O I
暂无
中图分类号
学科分类号
摘要
The clinical importance of Mycobacterium abscessus subsp. abscessus (M. abscessus) lung disease has been increasing, but few studies have assessed the clinical characteristics associated with the treatment outcome. We retrospectively analyzed 75 consecutive patients with M. abscessus lung disease diagnosed at a tertiary hospital from January 2004 to April 2018. Among 52 patients with sufficient clinical data, 19 patients (42.2%) achieved treatment success. Compared with 26 (57.8%) patients in the treatment failure group, body mass index (BMI) (19.8 vs 17.5 kg/m2, P = 0.022), previous nontuberculous mycobacterial (NTM) lung disease (26.3% vs 61.5%, P = 0.034), the presence of cavitary lesions (31.6% vs 69.2%, P = 0.017), and the bronchiectasis score (3.0 vs 5.0, P = 0.003) were significantly different in the treatment success group. Multivariate analysis showed that age (adjusted hazard ratio (aHR), 0.94; 95% confidence interval (CI), 0.90 to 0.99; P = 0.010), the presence of cavitary lesions (aHR, 0.34; 95% CI, 0.12 to 0.94; P = 0.039), and previous NTM lung disease (aHR, 0.28; 95% CI, 0.09 to 0.86; P = 0.026) were negatively associated with treatment success. This is the first study to show that previous NTM lung disease might be a clinically important factor related to unfavorable treatment outcomes in M. abscessus lung disease patients. To increase our understanding the characteristics of M. abscessus lung disease, this factor should be independently analyzed in future research.
引用
收藏
页码:247 / 254
页数:7
相关论文
共 50 条
  • [31] Clinical and Microbiologic Outcomes in Patients Receiving Treatment for Mycobacterium abscessus Pulmonary Disease
    Jarand, Julie
    Levin, Adrah
    Zhang, Lening
    Huitt, Gwen
    Mitchell, John D.
    Daley, Charles L.
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (05) : 565 - 571
  • [32] Clinical and Microbiological Differences between Mycobacterium abscessus and Mycobacterium massiliense Lung Diseases
    Harada, Toshiyuki
    Akiyama, Yasushi
    Kurashima, Atsuyuki
    Nagai, Hideaki
    Tsuyuguchi, Kazunari
    Fujii, Takashi
    Yano, Syuichi
    Shigeto, Eriko
    Kuraoka, Toshihiko
    Kajiki, Akira
    Kobashi, Yoshihiro
    Kokubu, Fumio
    Sato, Atsuo
    Yoshida, Shiomi
    Iwamoto, Tomotada
    Saito, Hajime
    JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (11) : 3556 - 3561
  • [33] The Clarithromycin Susceptibility Genotype Affects the Treatment Outcome of Patients with Mycobacterium abscessus Lung Disease
    Guo, Qi
    Chu, Haiqing
    Ye, Meiping
    Zhang, Zhemin
    Li, Bing
    Yang, Shiyi
    Ma, Wei
    Yu, Fangyou
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (05)
  • [34] Treatment Outcome in Patients with Mycobacterium abscessus Complex Lung Disease: The Impact of Tigecycline and Amikacin
    Yang, Jeng-How
    Wang, Ping-Huai
    Pan, Sheng-Wei
    Wei, Yu-Feng
    Chen, Chung-Yu
    Lee, Ho-Sheng
    Shu, Chin-Chung
    Wu, Ting-Shu
    ANTIBIOTICS-BASEL, 2022, 11 (05):
  • [35] Risk Factors for and Outcomes Following Early Acquisition of Mycobacterium abscessus Complex After Lung Transplantation
    Nick, Sophie E.
    Yarrington, Michael E.
    Reynolds, John M.
    Anderson, Deverick J.
    Baker, Arthur W.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (05):
  • [36] Mycobacterium abscessus infections: Epidemiology, clinical presentation and treatment
    Lerat, I.
    Truffot, C.
    Veziris, N.
    JOURNAL DES ANTI-INFECTIEUX, 2011, 13 (01) : 49 - 55
  • [37] Glycopeptidolipid Genotype Correlates With the Severity of Mycobacterium abscessus Lung Disease
    Li, Bing
    Ye, Meiping
    Zhao, Lan
    Guo, Qi
    Chen, Jianhui
    Xu, Benyong
    Zhan, Mengling
    Zhang, Yongjie
    Zhang, Zhemin
    Chu, Haiqing
    JOURNAL OF INFECTIOUS DISEASES, 2020, 221 : S257 - S262
  • [38] Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease
    Dedrick, Rebekah M.
    Freeman, Krista G.
    Nguyen, Jan A.
    Bahadirli-Talbott, Asli
    Cardin, Mitchell E.
    Cristinziano, Madison
    Smith, Bailey E.
    Jeong, Soowan
    Ignatius, Elisa H.
    Lin, Cheng Ting
    Cohen, Keira A.
    Hatfull, Graham F.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (07):
  • [39] Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series
    Pearson, Jeffrey C.
    Dionne, Brandon
    Richterman, Aaron
    Vidal, Samuel J.
    Weiss, Zoe
    Velasquez, Gustavo E.
    Marty, Francisco M.
    Sax, Paul E.
    Yawetz, Sigal
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (10):
  • [40] A pharmacologic approach to treatment of Mycobacterium abscessus pulmonary disease
    Kassegne, L.
    Veziris, N.
    Fraisse, P.
    REVUE DES MALADIES RESPIRATOIRES, 2024, 41 (01) : 29 - 42